PRESCRIPTION MEDICINE. Use only under the direction of a registered medical practitioner.
Intra Life generated product registryPRESCRIPTION · RxOfficial Intra Life brand information

Fosfomycin Sodium Injection / IV Infusion

FOSFODAY INJ

FOSFOMYCIN SODUM BP eq to fosfomycin 10gmInjection / IV Infusion

The official product source lists Urinary tract infections (UTIs), particularly acute cystitis caused by susceptible bacteria., Certain multidrug-resistant infections., Complicated urinary tract infections, Bone and joint infections, Respiratory tract infections, Bacteremia and sepsis (in combination therapy). This page does not independently expand or validate those uses.

FOSFOMYCIN SODUM BP eq to fosfomycin 10gm
Composition
Injection / IV Infusion
Dosage form
Packaging: 4gm; Pack Type: injection
Pack
2026-07-22
Last reviewed

Verified source information only. Confirm the current physical pack and locally approved information before use.

Source governed
Medical review gate active
FOSFODAY INJ verified official product image
Official product visual
Verified official product image retained with generated version 1.

Verified product record

One source of truth for FOSFODAY INJ

Public statements are limited to the approved evidence and review status recorded for this brand.

Generic

Fosfomycin Sodium

Composition

FOSFOMYCIN SODUM BP eq to fosfomycin 10gm

Therapeutic class

Antibiotic / Anti-infective

Pack

Packaging: 4gm; Pack Type: injection

Medical information

Evidence-aligned, safety-first explanation

Approved indication

Approved official product evidence displays: Urinary tract infections (UTIs), particularly acute cystitis caused by susceptible bacteria.; Certain multidrug-resistant infections.; Complicated urinary tract infections; Bone and joint infections; Respiratory tract infections; Bacteremia and sepsis (in combination therapy). Current local approved information governs clinical use.

Mechanism of action

Inhibits bacterial cell wall synthesis at an early stage.

Stewardship

Use only according to current approved local product information and qualified medical advice. Do not infer unsupported indications, dosing, performance, or outcomes from this page.

Dosage and administration

What the approved evidence says

Typical adult dose: 12–24 g/day IV, divided every 8–12 hours. Actual use must follow a registered medical practitioner and current local approved product information.

Administration guidance

Reconstitute with sterile water and dilute in suitable IV fluid; administer as slow IV infusion over 30–60 minutes; adjust dose in renal impairment as per creatinine clearance.

Prescription safeguard: This guide reproduces reviewed product evidence; it is not a personalized dose recommendation. Follow a registered medical practitioner and the current locally approved pack or insert.

Warnings and precautions

  • Diarrhea
  • Nausea
  • Vomiting
  • Headache
  • Dizziness
  • Hypokalemia
  • Increased liver enzymes
  • Injection site reactions
  • Allergic reactions (rare)
  • Seizures (rare, high doses) (explicitly stated)

Common adverse effects

  • Not supplied in the approved generated evidence; review current local prescribing information.

Relevant professional contexts

Registered Medical PractitionerHospital & Clinical PharmacyInstitutional Procurement

Professional and commercial pathways

A qualified route for every buyer

Start an enquiry

distribution

Discuss FOSFODAY INJ trade and territory requirements

Share your territory, firm type, and expected business requirement for an appropriate Intra Life trade follow-up.

Use this enquiry path

distribution

Connect for authorized distribution information

Submit your market, licence-ready organization context, and procurement requirement for business verification.

Use this enquiry path

distribution

Request verified brand and composition information

Use the enquiry path to discuss FOSFODAY INJ composition, pack, supply-channel requirements, and territory.

Use this enquiry path

distribution

Route a stockist or supply-chain enquiry

Provide your location and organization details so the relevant team can verify the appropriate supply route.

Use this enquiry path

retail

Verify the appropriate pharmacy supply route

Pharmacies can share their organization and location for product, pack, and supply-channel information. No online stock claim is made on this page.

Use this enquiry path

institutional

Request institutional product information

Hospital and institutional teams can submit formulary, pack, documentation, or procurement enquiries for review by the appropriate Intra Life team.

Use this enquiry path

Over 46 years of trust

Intra Life's current official homepage describes a legacy of over 46 years. This prototype uses that current wording and avoids older 43- or 45-year anniversary artwork found in other first-party materials.

Verify corporate source

Quality built through a carefully selected manufacturing network

Intra Life's official website presents a broad manufacturer network that includes established pharmaceutical production partners. The logos below reproduce the current official homepage carousel for corporate-network context only.

This corporate statement does not assign a certification, factory, or legal manufacturer to FOSFODAY INJ. Product-specific manufacturer and marketer details remain subject to current pack-panel verification.

Frequently asked questions

Clear answers from approved evidence

Evidence register

Reviewed sources

Intra Life product directory

Continue to another governed authority page for source-linked composition, medical context, dosage information, safety boundaries, and professional enquiry routes.

Only live static brands and current Go-Live-Ready generated releases are listed. Drafts, blocked versions, and archived releases remain excluded.

INTRA LIFE

This evidence-grounded page provides product and trade information. It does not diagnose, prescribe, or replace the current approved pack insert and professional medical advice.

FOSFODAY INJ

Information reviewed: 2026-07-22

Next scheduled review: 2026-10-20